Terms: = Prostate cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Prognosis
13 results:
1. Analysis of cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities.
Davies L; Milner DA; Shulman LN; Kyokunda L; Bedada A; Vuylsteke P; Masalu N; Jackson P; Jennings N; Odunlami A; Mtshali P; Dugan U
JCO Glob Oncol; 2023 Jun; 9():e2200203. PubMed ID: 37290022
[TBL] [Abstract] [Full Text] [Related]
2. Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study.
Cao G; Li Y; Wang J; Wu X; Zhang Z; Zhanghuang C; Han K
Front Public Health; 2022; 10():1028905. PubMed ID: 36330113
[TBL] [Abstract] [Full Text] [Related]
3. Protein signatures to distinguish aggressive from indolent prostate cancer.
Garcia-Marques F; Liu S; Totten SM; Bermudez A; Tanimoto C; Hsu EC; Nolley R; Hembree A; Stoyanova T; Brooks JD; Pitteri SJ
Prostate; 2022 Apr; 82(5):605-616. PubMed ID: 35098564
[TBL] [Abstract] [Full Text] [Related]
4. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml
Gao XD; Miao Q; Zhang JL; Zhai JZ; Gui XM; Cai YH; Niu Q; Cai B
Asian J Androl; 2022; 24(2):195-200. PubMed ID: 34916475
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
[TBL] [Abstract] [Full Text] [Related]
6. Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis.
Zhou J; Xia S; Li T; Liu R
BMC Cancer; 2019 Dec; 19(1):1186. PubMed ID: 31805980
[TBL] [Abstract] [Full Text] [Related]
7. YRNA expression in prostate cancer patients: diagnostic and prognostic implications.
Tolkach Y; Niehoff EM; Stahl AF; Zhao C; Kristiansen G; Müller SC; Ellinger J
World J Urol; 2018 Jul; 36(7):1073-1078. PubMed ID: 29492585
[TBL] [Abstract] [Full Text] [Related]
8. Uncontrolled diabetes predicts poor response to novel antiandrogens.
Karantanos T; Karanika S; Gignac G
Endocr Relat Cancer; 2016 Sep; 23(9):691-8. PubMed ID: 27515296
[TBL] [Abstract] [Full Text] [Related]
9. The use of aspirin and the risk of mortality in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
J Urol; 2015 Apr; 193(4):1220-5. PubMed ID: 25463991
[TBL] [Abstract] [Full Text] [Related]
10. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
Hagberg Thulin M; Jennbacken K; Damber JE; Welén K
Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404
[TBL] [Abstract] [Full Text] [Related]
11. Mortality in cancer patients with a history of cutaneous squamous cell carcinoma--a nationwide population-based cohort study.
Johannesdottir SA; Lash TL; Jensen AØ; Farkas DK; Olesen AB
BMC Cancer; 2012 Mar; 12():126. PubMed ID: 22458954
[TBL] [Abstract] [Full Text] [Related]
12. The role of high-grade prostatic intraepithelial neoplasia for biochemical relapse of prostate carcinoma after radical prostatectomy.
Auskalnis S; Milonas D; Jievaltas M; Vaiciūnas K; Mickevicius A; Gudinaviciene I
Medicina (Kaunas); 2010; 46(9):604-10. PubMed ID: 21252594
[TBL] [Abstract] [Full Text] [Related]
13. Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: implications for prevention and therapy.
Fernandez-Pol JA
Anticancer Res; 1996; 16(4B):2177-85. PubMed ID: 8694540
[TBL] [Abstract] [Full Text] [Related]
